US Provides 500,000 Dengue Test Kits to Bangladesh

DHAKA — The United States has provided 500,000 dengue NS1 rapid diagnostic test kits to Bangladesh to support the country’s ongoing efforts to detect dengue cases and strengthen treatment management. The kits were provided through the STRIDES programme, funded by the US government, according to a press release. US Chargé d’Affaires to Bangladesh Trishita Maula formally handed over the kits to Health and Family Welfare Minister Sardar Md Sakhawat Husain at Kurmitola Multicare Specialized Hospital in Dhaka on Thursday morning.

Speaking at the handover ceremony, the health minister directed the authorities concerned to distribute the dengue testing kits across the country promptly. He said the ceremony was held at Kurmitola Multicare Specialized Hospital considering traffic congestion and transportation convenience. “However, all the handed-over kits will be deposited directly with the Central Medical Stores Depot (CMSD). Subsequently, the kits will be sent to district and upazila hospitals across the country through the Directorate General of Health Services (DGHS), based on demand,” Sakhawat said. The minister said the government currently has adequate stocks of dengue antigen test kits and intravenous saline in addition to the newly received supplies.

“As a result, the health sector is prepared to ensure necessary testing and treatment even if the number of dengue cases increases in any part of the country,” he said. On the possibility of introducing a dengue vaccine in Bangladesh, Sakhawat said the government was considering the option but stressed the importance of ensuring the vaccine’s efficacy and safety because of its high cost.

“Since the vaccine is costly, it is important to ensure its efficacy and safety,” he said. Discussions are underway with the World Health Organization (WHO), UNICEF and Gavi on the issue, the minister said, adding that a final decision would be taken in line with international guidelines.

Additional Secretary of the Health Services Division Md Rafiqul Islam, Additional Director General of the DGHS Professor Dr Md Zahid Raihan, Director of Kurmitola Multicare Specialized Hospital Brigadier General Md Saydur Rahman, and senior officials from the US Embassy and the Ministry of Health and Family Welfare attended the programme. Later, the minister visited the hospital’s dengue ward and diagnostic laboratory.




Trump Announces Drug-Price Deals With 9 More Pharmaceutical Companies

Shibbir Ahmed, WASHINGTON DC — President Donald Trump on Monday announced new agreements with nine pharmaceutical manufacturers aimed at lowering prescription drug prices for Americans, expanding his administration’s effort to tie U.S. drug prices to the lower prices paid in other developed countries.

The White House said the agreements bring the total number of pharmaceutical manufacturers participating in the administration’s Most-Favored-Nation (MFN) drug-pricing program to 26, covering about 89% of the branded-drug market.

The nine companies joining the latest agreements are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB.

Under the agreements, the companies will provide MFN pricing to state Medicaid programs across the United States on eligible medicines. The White House said the deals cover drugs used to treat a range of serious and chronic conditions, including hemophilia, Parkinson’s disease, macular degeneration, glaucoma, liver disease, skin conditions and cancer.

The administration’s MFN strategy seeks to align prices paid in the United States with the lowest prices paid by comparable developed nations.

$19.6 Billion U.S. Manufacturing Investment

The new agreements also include commitments to strengthen pharmaceutical manufacturing in the United States. According to the White House, the nine companies have collectively committed to invest at least $19.6 billion in U.S. manufacturing in the near term.

Several companies have additionally agreed to provide active pharmaceutical ingredients to the federal government’s Strategic Active Pharmaceutical Ingredients Reserve, which is intended to strengthen domestic pharmaceutical supply chains and reduce dependence on foreign sources.

UCB, for example, will contribute 163 tons of levetiracetam, a drug used to control and prevent seizures. Sun Pharma will contribute supplies of the antibiotics clindamycin and doxycycline, while Teva will provide metronidazole and amlodipine. Astellas will contribute tacrolimus, an immunosuppressant used to help prevent organ rejection following transplants.

Administration Projects Major Savings

The White House says patients have already saved more than $700 million through TrumpRx, the administration’s prescription-drug discount platform, since its launch in February.

The administration also says more than 500,000 seniors have saved a combined $216 million since July through a program offering certain GLP-1 obesity medicines for $50 a month to seniors without coverage for those drugs.

The White House’s Council of Economic Advisers estimates that the administration’s broader MFN agreements could generate approximately $600 billion in savings over the next decade. That figure is an administration estimate rather than an independently verified projection.

Part of Trump’s Broader Drug-Pricing Push

Trump ordered his administration in May 2025 to pursue Most-Favored-Nation pricing for prescription medicines, seeking to bring U.S. prices closer to those paid in other developed countries.

The administration subsequently reached agreements with major pharmaceutical manufacturers, including Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Merck, Novartis, Sanofi and others.

Trump launched TrumpRx.gov in February 2026 as part of the administration’s effort to make lower-priced medicines available directly to American consumers through participating manufacturers and pharmacies.

Reuters reported Monday that the latest agreements include a mix of international pharmaceutical companies and smaller biotechnology firms, expanding the program beyond the large drugmakers that participated in earlier rounds.

The new agreements come as prescription-drug affordability remains a major issue for American consumers and as the Trump administration prepares for the November midterm elections.

The White House is also calling on Congress to advance what it describes as the “Great Healthcare Plan,” which the administration says would seek to lower drug prices and insurance premiums while increasing price transparency.

For Americans, the practical impact of Monday’s agreements will depend on which medicines receive the new pricing arrangements, when the lower prices take effect and how the discounts are implemented through Medicaid and participating drug programs. The White House announcement marks the latest and one of the largest expansions of Trump’s MFN drug-pricing initiative since it began in 2025.